Inhibrx, Inc.
(NASDAQ GM: INBX)
Rigrodsky Law, P.A. is investigating Inhibrx, Inc. (“Inhibrx”) regarding possible breaches of fiduciary duties and other violations of law related to Inhibrx’s agreement to be acquired by Sanofi. Under the terms of the agreement, Inhibrx shareholders will receive $30.00 per share in cash, a contingent value right of $5.00, conditioned upon the achievement of a regulatory milestone, and 0.25 shares of a new publicly traded company that will retain Inhibrx's non-INBRX-101 assets.